Leramistat

Leramistat (HMC-C-01-A; MBS2320) is a mitochondrial complex 1 inhibitor, involving in cell metabolism immune metabolism regulation. Leramistat also inhibits ATP production in Thp1 human monocytes (IC50: 0.63 μM) . Leramistat inhibits atopic dermatitis and other skin diseases autoimmune diseases, inflammatory diseases, cancer; and also inhibits osteoclast mediated disease[1][2][3].

Product Specifications

CAS Number

[1642602-54-7]

Product Name Alternative

HMC-C-01-A; MBS2320

UNSPSC

12352005

Hazard Statement

H302

Target

Mitochondrial Metabolism

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/leramistat.html

Purity

98.00

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

N#CC1=C(C2=CC=C(C=C2)S(N[C@H]3CC[C@](O)(CC3)C)(=O)=O)C=CC(Cl)=C1

Molecular Formula

C20H21ClN2O3S

Molecular Weight

404.91

Precautions

H302

References & Citations

[1]Pokharel MD, et al. Mitochondrial network dynamics in pulmonary disease: Bridging the gap between inflammation, oxidative stress, and bioenergetics. Redox Biol. 2024 Apr;70:103049. |[2]Preparation of 1-methyl-4-[ (4-phenylphenyl) sulfonylmethyl]cyclohexanol and 1-methyl-4-[[4- (2-pyridyl) phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use. World Intellectual Property Organization, WO2020035560 A1 2020-02-20.|[3]Preparation of N- (4-hydroxy-4-methyl-cyclohexyl) -4-phenyl-benzenesulfonamides and N- (4-hydroxy-4-methyl-cyclohexyl) -4- (2-pyridyl) benzenesulfonamides and their therapeutic use. World Intellectual Property Organization, WO2014207445 A1 2014-12-31.